<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715998</url>
  </required_header>
  <id_info>
    <org_study_id>QGC001-2QG4</org_study_id>
    <nct_id>NCT03715998</nct_id>
  </id_info>
  <brief_title>Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction</brief_title>
  <acronym>QUORUM</acronym>
  <official_title>A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction After Acute MI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quantum Genomics SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Quantum Genomics SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2&#xD;
      study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily&#xD;
      doses) versus ramipril administered orally BID over 12 weeks after acute anterior MI.&#xD;
&#xD;
      Subjects will be followed for 12 weeks (over 4 study visits). A total of 294 male and female&#xD;
      subjects with a diagnosis of first acute anterior MI will be randomized. The subjects will&#xD;
      need to have a primary percutaneous coronary intervention (PCI) of the index MI related&#xD;
      artery within 24 hours after MI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At Inclusion Visit (Visit 2 [within 72 hours after acute MI]), subjects will be randomly&#xD;
      assigned to 1 of the following 3 treatment groups in a 1:1:1 ratio:&#xD;
&#xD;
        -  Group 1: Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for&#xD;
           10 weeks&#xD;
&#xD;
        -  Group 2: Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for&#xD;
           10 weeks&#xD;
&#xD;
        -  Group 3: Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10&#xD;
           weeks&#xD;
&#xD;
      Then subjects will undergo study procedures at Titration Visit (Visit 3 [Day 14]), Treatment&#xD;
      Visit (Visit 4 Day 42]) and End-of-Treatment Visit (Visit 5 [Day 84]).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction assessed by cardiac magnetic resonance imaging (CMRI)</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of the effects of BID oral administration of 2 doses of firibastat to those of BID oral administration of ramipril on the change from Baseline in LVEF on Day 84</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left-ventricle end-diastolic volume assessed by CMRI</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of the effects of BID administration of firibastat and ramipril on the change from Baseline to Day 84 in left-ventricle end-diastolic volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left-ventricle end-systolic volume assessed by CMRI</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of the effects of BID administration of firibastat and ramipril on the change from Baseline to Day 84 in left-ventricle end-systolic volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiac event (MACE): combined clinical endpoint of cardiovascular death, MI, and cardiac hospitalization</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of the effects of BID administration of firibastat and ramipril on major cardiac event (MACE) over 84 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal pro b-type natriuretic peptide (NT proBNP)</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of the effects of BID administration of firibastat and ramipril on the change from Baseline to Day 84 in N-terminal pro b-type natriuretic peptide (NT proBNP)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Group 1: firibastat 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: firibastat 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: ramipril 2.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>1 or 2 capsules administered orally, twice daily</description>
    <arm_group_label>Group 3: ramipril 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Firibastat</intervention_name>
    <description>1 or 2 capsules administered orally, twice daily</description>
    <arm_group_label>Group 1: firibastat 50 mg</arm_group_label>
    <arm_group_label>Group 2: firibastat 250 mg</arm_group_label>
    <other_name>QGC001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of first acute anterior MI (ST-elevation myocardial infarction) defined as&#xD;
             chest pain &gt;30 minutes and ST elevation ≥0.2 mV in at least 2 consecutive&#xD;
             electrocardiogram (ECG) leads in the anterior area (DI, aVL, V1 V6).&#xD;
&#xD;
          -  Primary PCI of the index-MI-related artery within 24 hours after the MI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index &gt;45 kg/m².&#xD;
&#xD;
          -  Subject is hemodynamically unstable or has cardiogenic shock.&#xD;
&#xD;
          -  Subjects with clinical signs of HF (Kilipp III and IV).&#xD;
&#xD;
          -  Systolic blood pressure &lt;100 mmHg at inclusion visit&#xD;
&#xD;
          -  Early primary PCI of the index-MI-related artery performed within 3 hours after MI.&#xD;
&#xD;
          -  Subjects treated with angiotensin-converting-enzyme inhibitor (ACE I), angiotensin&#xD;
             receptor blocker (ARB) or sacubitril/valsartan prior to the index magnetic resonance&#xD;
             imaging. Note: if treatment was for HTN, ACE I/ARB should be stopped, and, if&#xD;
             necessary, another therapeutic class can be prescribed for HTN. If the ACE I/ARB was&#xD;
             prescribed for congestive HF, the subject is not considered eligible; if the ACE I/ARB&#xD;
             prescribed for another reason cannot be stopped, the subject is not eligible for study&#xD;
             inclusion.&#xD;
&#xD;
          -  Subjects scheduled for implantable cardioverter defibrillator (ICD), cardiac&#xD;
             resynchronization therapy, or pacemaker within the next 3 months. If an ICD is&#xD;
             indicated for ventricular arrhythmia during the course of the study, a life vest, when&#xD;
             possible, should be prescribed and the ICD scheduled after study completion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Montalescot, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Pitié-Salpêtrière - Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Besse, MD</last_name>
    <phone>+33 1 85 34 77 70</phone>
    <email>bruno.besse@quantum-genomics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariette Codou, PharmD</last_name>
    <phone>+33 (0)1 85 34 77 74</phone>
    <email>mariette.codou@quantum-genomics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpêtrière - Institut de Cardiologie</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Montalescot</last_name>
      <phone>+33 1 42 16 29 59</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UKSH Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Hungarian Army</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert KISS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawła II</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Legutko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NUSCH Bratislava Dpt. of Acute Cardiology</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek ORBAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz,</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Antorrena, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital Newcastle upon Tyne</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian PURCELL, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Firibastat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

